Bayer bolsters bio-digital efforts with licensing of One Drop's AI-driven platform for use in multiple therapeutic areas

One Drop on Tuesday announced $40 million in Series B financing, led by Bayer, which has also agreed to use One Drop's platform in its global bio-digital efforts in therapeutic areas such as oncology, cardiovascular disease and women's health. Bayer Pharmaceuticals president Stefan Oelrich, who will join One Drop's board, said "this collaboration allows us to obtain access to a world leading self-care platform for disease management beyond the boundaries of medicines with strong artificial intelligence (AI)-driven capabilities."

Jeff Dachis, chief executive at One Drop, said his company is leveraging the global digital infrastructure to "provide evidence-based, hyper-personalised diabetes support." He added that Bayer's move to become an investor and commercial partner "[validates our] superior user experience, modular and extensible product offering, and ability to bring affordable, accessible healthcare to millions of people worldwide."

Through the licensing agreement, Bayer will use One Drop's data science and predictive capabilities, as well as harness its mobile capabilities, to deliver bio-digital solutions across a wide range of therapeutic areas. One Drop explained that its digital platform provides personalised health programmes to help achieve "sustainable behaviour change" for patients with diabetes via AI-powered behavioural recommendations, one-on-one coaching and thousands of app and device integrations. However, the company noted that its integrated platform allows people to easily track and manage a variety of health conditions.

In 2016, One Drop's blood glucose monitoring system One Drop | Chrome received FDA 510(k) clearance and CE mark approval. Last month, MannKind and One Drop entered into a collaborative agreement that is intended to integrate MannKind's BluHale accessory device into the One Drop platform.  

To read more Top Story articles, click here.